Blend uniformity is an important factor in pharmaceutical manufacturing. A poor uniformity of the blend can cause the rejection of the product that can lead to the loss of revenue.No method is developed yet to determine the uniformity of blend during the mixing. Therefore, blending is a critical process that can affect the quality of the product. When active material is added in small quantity in the batch, sandwich method of blending should be employed where active material is added between the layers of the excipients and mixed.
Particle size of the formulation ingredients can affect the physical properties of the product. Dissolution of the tablets is affected by the particle size of active ingredients.
De-mixing of the blend ingredients may occur due to the over blending of the bland. It can cause the segregation of the active material in the bland and finally can show the results out of blend uniformity limits. Therefore, it is important to validate the mixing time in the manufacturing process.
Related: Sampling Procedure for Blander
Particle size of the ingredients plays a great role in the de-mixing process. A big difference in the particle size of the active ingredients and the excipients may cause the de-mixing. A fine powder form of the ingredients should be avoided. Unloading of the blend should be done carefully to avoid the de-mixing.
According to the FDA’s Blend Uniformity Analysis, sample taken for the bland uniformity analysis should be equivalent to the weight of the dosage form and whole sample should be taken for analysis. Blend uniformity analysis is not necessary to done when active ingredient in each dosage form is 50 mg or grater and when dosage unit contains more then 50 % of active ingredient. Blend is analyzed for uniformity of active contents to comply the limit (85-115%)
According to 21 CFR 211.110 (a) (3) proper mixing of the ingredients is required to ensure the uniformity of content.
Segregation of the active material may occur when sample is place on any vibrating surface that can cause the analytical error. Blending process is a GMP activity therefore it should be done and monitor carefully.
Ankur Choudhary is India's first professional pharmaceutical blogger, author and founder of Pharmaceutical Guidelines, a widely-read pharmaceutical blog since 2008. Sign-up for the free email updates for your daily dose of pharmaceutical tips.
Email: .moc.enilediugamrahp@ofni Need Help: Ask Question
Spread the Knowledge ⇩⇩⇩